How do I switch a patient from a 1 mg oral tablet to a transdermal patch?

Switching from 1 mg Oral Granisetron to Transdermal Patch

Apply one 3.1 mg/24-hour granisetron transdermal patch (containing 34.3 mg total granisetron) approximately 24–48 hours before discontinuing the 1 mg oral tablet, and remove the oral dose once the patch is in place. 1

Patch Application and Timing

• Apply the patch to clean, dry skin on the upper outer arm 24–48 hours before the first chemotherapy dose (or before discontinuing oral therapy if switching for ongoing treatment). 1
• The patch delivers granisetron continuously at approximately 2.08 micrograms per hour for the standard 50 mcg/24-hour estradiol patch formulation, though granisetron patches are dosed as 3.1 mg/24 hours. 2
• Maximum patch duration is 7 days, after which it should be replaced if continued antiemetic coverage is needed. 1
• Rotate application sites with each new patch to minimize skin irritation. 3

Dose Equivalency Rationale

• The 1 mg oral granisetron dose is considered therapeutically equivalent to the 3.1 mg/24-hour transdermal patch for chemotherapy-induced nausea and vomiting (CINV) prevention. 1
• Both formulations are listed as interchangeable options across all emetogenic risk categories (high, moderate, and low) in ASCO antiemetic guidelines. 1
• The transdermal route provides steady-state drug delivery over multiple days, eliminating the need for daily oral dosing. 1

Switching Protocol

• For patients currently taking 1 mg oral granisetron daily, apply the patch and discontinue the oral tablet on the same day. 1
• If switching in the context of multiday chemotherapy, apply the patch 24–48 hours before the first chemotherapy dose and maintain it throughout the chemotherapy cycle plus 2 days thereafter. 1
• No dose titration or overlap period is required when switching between these equivalent formulations. 1

Clinical Advantages of the Patch

• The transdermal patch eliminates daily pill burden and provides continuous antiemetic coverage for up to 7 days, which is particularly beneficial for multiday chemotherapy regimens. 1
• Patients who experience nausea or vomiting that interferes with oral medication absorption may achieve more reliable drug delivery with the patch. 1
• The patch is appropriate for all emetogenic risk categories when combined with appropriate corticosteroids and NK₁ receptor antagonists as indicated. 1

Common Pitfalls to Avoid

• Do not apply the patch to irritated, damaged, or recently irradiated skin, as this may alter absorption or cause local reactions. 3
• Ensure the patch is firmly adhered throughout its wear time; if it falls off prematurely, apply a new patch to a different site and restart the 7-day clock. 1
• Do not cut or divide the patch, as this disrupts the drug-in-adhesive matrix and alters the delivery rate. 2
• Remember that the patch alone does not provide complete antiemetic prophylaxis for moderate- or high-emetogenic chemotherapy—it must be combined with dexamethasone (and NK₁ antagonists for high-risk regimens). 1